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diseases are a relatively new area of inﬂammation, but have a vastly
expanding spectrum of diseases.
Inﬂammatory brain diseases, including infectious meningitis, en-
cephalitis, vasculitis, T-cell mediated inﬂammatory brain diseases, and
demyelinating diseases are rare diseases and would beneﬁt from a pre-
cisionmedicine approach. The spectrum of inﬂammatory brain diseases
has rapidly expanded during the last decade and keeps expanding with
new discoveries (Twilt and Benseler, 2014). Diseases such as small ves-
sel primary CNS vasculitis, previously only diagnosed on autopsy, arePrecision medicine, also known as stratiﬁed medicine or personal-
ized medicine, aims to better target intervention to the individual,
maximize beneﬁt and minimize harm. Enthusiasm for the prospect of
precision medicine has grown signiﬁcantly in the last few years. There
has been increasing interest in two streams of development in precision
medicine. First is the integration of electronicmedical records capturing
longitudinal data and providing clinical phenotypes into decision mak-
ing tools for precisionmedicine. Secondly, the advance in genomicmed-
icine and pharmacogenomics research provides an expanding arsenal of
genetic predictors of disease and health outcomes. Together these two
streams provide a unique framework for an individualized diagnostic
and therapeutic approach. Genetics has been a part of the health care
system since introduction of the newborn screening in the 1960s, now
it has become a priority area for prevention and treatment of common
chronic diseases such as cancer and heart diseases (Auffray et al.,
2016). In cancer research, personalized medicine based on genomics
and pharmacogenomics is expanding rapidly. Other chronic diseases,
such as diabetes and neurodegenerative diseases have widened their
horizons and included precision medicine in their research strategies.
Inﬂammation appears in a wide spectrum of diseases and has a very
heterogeneous phenotype, including autoimmune diseases such as
systemic lupus erythematosus and rheumatoid arthritis to
autoinﬂammatory diseases and immunodysregulatory diseases such
as secondary hemophagocytic lymphohistiocytosis. In the last
25 years, the understanding of inﬂammatory diseases has dramatically
increased and changed our approach to treatment. Initially these
under-recognized childhood and adult diseases were associated with
high burden of disease and associated high mortality rates. In rheuma-
toid arthritis, the single discovery of the cytokine TNF-alpha has
changed a joint-destructing debilitating disease refractory to treatmentom.2016.01.008.
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.now increasingly recognized early in the disease course, before irrevers-
ible neurological deﬁcits are developed. One of the big challenges in in-
ﬂammatory brain diseases is the overlapping clinical phenotype and
absence of genetic markers and disease speciﬁc biomarkers for most
diseases. Verhey et al. (2013), developed a scoring system to evaluate
brain MRIs of children with demyelinating diseases. The scoring too
was tested on MRIs of patients with demyelinating diseases (acute dis-
seminated encephalomyelitis (ADEM) andmultiple sclerosis (MS)) and
small vessel CNS vasculitis because these disorders share clinical fea-
tures rendering accurate diagnosis challenging at onset. Although the
inter-rater agreement of many features was acceptable, there were
items that demonstrated acceptable inter-rater agreement but did not
aid in differentiating ADEM, MS and small vessel CNS vasculitis on
MRI. These authors made a signiﬁcant step towards precisionmedicine
but other factors must to be added to the equation before barriers in di-
agnosing these diseases are lifted.
Due to the heterogeneity of inﬂammatory brain diseases, the devel-
opment and implementation of one simple automated classiﬁcation
tool seem extremely difﬁcult. Even so, the study by Obermeier et al
(2016), uses a tool to enable physicians to ask the correct questions at
the right time, thereby classifying cases consistently and accurately
and facilitating translational research. The implemented Vienna Vaccine
Safety Initiative Automated Case Classiﬁcation-tool (VACC-Tool) was
used to identify early common infectious and rarer inﬂammatory
brain diseases (demyelinating diseases). Although the tool left some
cases indeterminate (when doctors in routine care failed to obtain the
necessary laboratory tests), this is the ﬁrst step in classiﬁcation of in-
ﬂammatory brain diseases using a precision medicine approach, and
could potentially be expanded to the whole spectrum of brain diseases
The next step would be to include biomarkers, proteomics and geno-
mics to further develop precisionmedicine strategies leading to person-
alized medicine for patients with inﬂammatory brain diseases
Currently most treatment strategies include potent immunotherapy
with severe side-effects. Inﬂammatory brain diseases are not the only
neurological area precision medicine holds a future. Several studies
25M. Twilt / EBioMedicine 4 (2016) 24–25have looked at the role of personalized medicine in mood disorders, au-
tism and related neurodegenerative disorders (Alhajji and Nemeroff,
2015; Sahin and Sur, 2015). All studies have one thing in common,
they all combine clinical phenotypes with genomics and proteomics,
feeding back to the two big streams in precision medicine.
In the next coming yearsmany genomic discovery platforms in com-
bination with clinical phenotyping based on electronic medical record
data will lead to more insight with respect to disease processes and
lead to more individualized targeted treatment (Smoller et al., 2016).
Overall the use of clinical phenotype and classiﬁcation tools help to di-
agnose diseases early to allow a more rapid introduction of targeted
treatment avoiding harm and increasing beneﬁt.
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